Literature DB >> 7965225

The protective role of bilirubin in oxygen-radical diseases of the preterm infant.

T Hegyi1, E Goldie, M Hiatt.   

Abstract

We hypothesized that because bilirubin is a potent free-radical quencher, infants without disorders that have oxygen-radical disease (ORD)-mediated mechanisms may have higher bilirubin levels than infants suffering from conditions possibly associated with ORD-mediated mechanisms (e.g., necrotizing enterocolitis, broncopulmonary dysplasia, intraventricular hemorrhage, and retinopathy of prematurity). We identified 25 infants (birth weight 912 +/- 208 gm, gestational age 27 +/- 3 weeks) who comprised the ORD group and compared them with 57 controls (birth weight 1242 +/- 248 gm, gestational age 31 +/- 3 weeks). Infants with ORD had lower peak serum bilirubin concentrations, later ages at peak, and lower incidence of peak bilirubin concentrations exceeding 10 or 15 mg/dl. In addition, these infants exhibited a slower rate of bilirubin rise and a smaller area under the bilirubin-time curve measure compared with controls. To control for different birth weights, we analyzed subgroups weighing < 1000 gm. Significant differences were again identified in peak bilirubin concentrations, age at peak, phototherapy duration, and area under the curve. In this population of preterm infants, higher bilirubin levels were associated with a lower incidence of oxygen radical-mediated injury.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7965225

Source DB:  PubMed          Journal:  J Perinatol        ISSN: 0743-8346            Impact factor:   2.521


  15 in total

1.  Oxidative stress, phototherapy and the neonate.

Authors:  G Gathwala; S Sharma
Journal:  Indian J Pediatr       Date:  2000-11       Impact factor: 1.967

2.  Antioxidant properties of blirubin in the model organism, Caenorhabditis elegans.

Authors:  Danny McCaughan; Catherine Au; Alexandre Benedetto; Dejan Milatovic; Judy Aschner; Michael Aschner
Journal:  Int J Neuroprot Neuroregener       Date:  2008

3.  Reduced expression of UGT1A1 in intestines of humanized UGT1 mice via inactivation of NF-κB leads to hyperbilirubinemia.

Authors:  Ryoichi Fujiwara; Shujuan Chen; Michael Karin; Robert H Tukey
Journal:  Gastroenterology       Date:  2011-10-06       Impact factor: 22.682

4.  Bilirubin, formed by activation of heme oxygenase-2, protects neurons against oxidative stress injury.

Authors:  S Doré; M Takahashi; C D Ferris; R Zakhary; L D Hester; D Guastella; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

Review 5.  Neural roles for heme oxygenase: contrasts to nitric oxide synthase.

Authors:  D E Barañano; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

6.  Enteral supplements of a carbon monoxide donor CORM-A1 protect against cerebrovascular dysfunction caused by neonatal seizures.

Authors:  Jianxiong Liu; Alexander L Fedinec; Charles W Leffler; Helena Parfenova
Journal:  J Cereb Blood Flow Metab       Date:  2014-11-05       Impact factor: 6.200

Review 7.  Cerebroprotective functions of HO-2.

Authors:  Helena Parfenova; Charles W Leffler
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

Review 8.  Treatment of jaundice in low birthweight infants.

Authors:  M J Maisels; J F Watchko
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-11       Impact factor: 5.747

9.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Authors:  E Beutler; T Gelbart; A Demina
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Triterpenoid electrophiles (avicins) activate the innate stress response by redox regulation of a gene battery.

Authors:  Valsala Haridas; Margaret Hanausek; Goshi Nishimura; Holly Soehnge; Amos Gaikwad; Maciej Narog; Erick Spears; Robert Zoltaszek; Zbigniew Walaszek; Jordan U Gutterman
Journal:  J Clin Invest       Date:  2004-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.